Pancragen is a short synthetic peptide from the Khavinson “bioregulator” family, marketed as a pancreas-focused regulator, with some vendor material framing it around blood sugar and pancreatitis-related themes. It is sold mainly as an oral capsule by longevity and biohacking resellers rather than as a registered medicine.
Research snapshot
| Peptide category | Khavinson-family short “bioregulator” peptide, marketed as a pancreas-focused regulator |
| Primary research interest | Pancreatic tissue support; some vendor material frames it around blood sugar and pancreatitis-related themes |
| Highest available evidence | Unverified — vendor sources are inconsistent about the exact sequence (tripeptide vs. tetrapeptide claims); no single sequence reliably repeated across independent, authoritative sources |
| Human research available | No — no human clinical trial identified |
| Development status | Not in formal pharmaceutical development; sold mainly as an oral capsule by longevity/biohacking resellers |
| Regulatory status | Not an approved drug anywhere |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Pancragen |
| Alternative names | Marketed as part of the Khavinson bioregulator peptide line |
| Peptide sequence | Not reliably established — vendor sources are inconsistent, with some listing a tripeptide and others a tetrapeptide; no specific sequence is asserted here as confirmed |
| Amino-acid length | Not reliably established |
| Molecular formula | Not independently verified in this pass |
| Molecular weight | Not independently verified in this pass |
| CAS Registry Number | Not reliably established |
| PubChem CID | Not reliably established |
| Peptide class | Khavinson-group “bioregulator” peptide line |
| Primary biological target | Not established — proposed pancreatic tissue activity, not confirmed via primary literature |
| Developer or originator | Vladimir Khavinson’s laboratory, for the broader bioregulator line |
| Development status | Not an approved or registered pharmaceutical anywhere identified in this review |
What it is
Pancragen is part of the same short-peptide bioregulator concept developed by Vladimir Khavinson’s laboratory, proposed to act on pancreatic tissue. Vendor sources are inconsistent about its exact sequence, with some listing a tripeptide and others a tetrapeptide; PeptideBlog.net was unable to identify a single sequence reliably repeated across independent, authoritative sources, so no specific sequence is asserted here as confirmed.
Some reseller pages describe Pancragen with more specific therapeutic framing than most other bioregulators in this family — for example, referencing chronic pancreatitis or diabetes — which reads closer to unverified marketing language than to a documented indication. No such indication has been evaluated by any Western regulator, and no clinical trial supporting a diabetes- or pancreatitis-specific claim was identified.
No confirmed CAS number, PubChem CID, or UNII record was located for Pancragen. It is not FDA approved and does not appear to hold independent pharmaceutical registration in Russia; it circulates as a supplement.
How does it work?
Plain-English explanation
The proposed idea is that Pancragen supports normal pancreatic cell function, which vendor marketing sometimes extends toward blood sugar regulation or general metabolic support. This has not been demonstrated in controlled human studies.
Technical explanation
Consistent with the broader bioregulator framework, the proposed mechanism is short-peptide modulation of gene expression in pancreatic tissue, potentially including both exocrine and endocrine (islet) cells depending on which vendor description is used. This has not been independently confirmed, and no pharmacokinetic data for oral use was identified.
Potential benefits and research applications
Pancreatic tissue and metabolic support
What is being investigated: whether Pancragen supports normal pancreatic function, including exocrine digestive-enzyme production or endocrine (insulin-related) activity, per vendor materials. How the effect might occur: proposed gene-regulatory action in pancreatic tissue. Evidence: limited animal/mechanistic work attributed to the originating Russian group; independent replication was not identified. Strength: weak (Tier 3/4 at best). Limitation: no controlled human data on blood sugar, insulin, or pancreatitis outcomes was found, and marketing claims referencing diabetes or chronic pancreatitis go well beyond what any identified source actually demonstrates.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
No established or reliably sourced dosing information was identified.
Amounts studied in animal research
Not consistently reported. No extractable, Pancragen-specific animal dose figures were identified in the sources reviewed.
Practitioner and community-reported protocols
Vendor pages commonly describe 10-20 mg oral capsules, one capsule daily, in cycles of roughly 10-20 days. This is vendor/community-reported (Tier 6) information, and its original clinical source could not be verified.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| General pancreatic/metabolic support (community use) | Oral capsule | 10-20 mg per capsule | Once daily | Roughly 10-20 day cycles |
Vendor sources commonly describe 10-20 mg oral capsules taken once daily for about 10-20 days.
This is widely repeated online, but its original source could not be verified against any published clinical protocol.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No systematic human safety data was identified. General risks applicable to unregulated peptide supplements apply: unverified purity and identity, uncertain oral bioavailability, absence of long-term safety monitoring, and supply-chain risks. Anyone with diabetes or pancreatic disease relying on unverified vendor marketing language instead of a licensed clinician’s guidance should be aware that no clinical evidence supports Pancragen for these conditions.
Regulatory and developmental status
Pancragen is not FDA approved and has no FDA-recognized indication. No independent pharmaceutical registration was identified in Russia; it circulates as a supplement. Status verified as of the review date below.
Frequently asked questions
What is Pancragen?
Pancragen is a short Khavinson-family synthetic peptide marketed as a pancreas-focused bioregulator, sold mainly as an oral supplement.
Does Pancragen treat diabetes or pancreatitis?
No clinical evidence supporting such a claim was identified. Some vendor marketing references these conditions, but this appears to be unverified marketing language rather than a documented, evidence-based indication.
What dosage has been studied in humans?
No established or reliably sourced human dosing information was identified.
What dosage commonly circulates online?
Vendors commonly describe 10-20 mg oral capsules taken once daily for roughly 10-20 days; this is vendor/community-reported, not a clinical dose.
Is Pancragen approved by any regulator?
No. No FDA or other formal regulatory approval was identified.
Bottom line
Pancragen is a thinly documented Khavinson-family peptide marketed for pancreatic support, with some vendor pages extending its claims toward diabetes or pancreatitis without supporting clinical evidence. What underlying research exists is limited to animal/mechanistic work from the originating group, and no reliable, independently confirmed sequence or chemical identifier could be established.